Skip to main content
← All comparisons

Best Pharma Pipeline Tracking Software in 2026

Maven Bio provides live intelligence that keeps pipeline assessments current with source-linked edits to selected working files1. For example, Maven Bio carries relevant developments into maintained assessments1, Citeline Pharmaprojects+ follows drug development from preclinical research to launch2, and DataLookout tracks changes in ClinicalTrials.gov records3.

This guide compares how teams continuously monitor competitors in pharma through maintained files, curated development records, and registry changes, covering pipeline tracking software for development research, pipeline monitoring, and recurring assessments in 2026123. The shortlist includes development databases, connected research platforms, and a focused registry monitor, with each product's scope stated alongside its capabilities43.

Best Pharma Pipeline Tracking Software in 2026

Jump to a platform

How we assessed these platforms

The assessment uses public product pages, help centers, and developer documentation checked in November 2026. It examines the evidence each platform brings into research, the changes it follows, and the outputs it maintains. Maven Bio publishes this guide, and its own entry is held to the same evidence standard, with every claim linked to a public page.

CriterionWhat we checked
Development and clinical evidenceDrug, trial, and company records, with the stated development stages and source boundaries
Pipeline monitoringDevelopment changes, FDA actions, clinical trial readouts, and recurring research
Evidence traceabilityLinks to source documents and records behind a finding or an edit
Working filesSource-linked revisions, editable deliverables, revision history, and rollback
Connected researchMCP, API, and connectors that carry evidence into assistants or internal systems

The guide does not give an overall score. Teams weigh these criteria differently, so each entry below names the work the platform suits best, its published coverage, its price on record, and its limitations, and the quick picks above match platforms to common use cases8.

Pipeline tracking tasks compared

Maven Bio documents maintained project files, while Citeline describes preclinical-to-launch development coverage and historical pipeline snapshots12. The forecast column covers a provider-supplied consensus sales dataset, which Maven Bio says it does not produce and Cortellis exposes through CCI95.

PlatformClinical-trial researchDevelopment or registry changesFile delivery and maintained revisionsMCP connectionProvider consensus sales forecast dataset
Maven Bio11011YesYesSource-linked edits, history, and rollbackYesNo9
Citeline Pharmaprojects+2YesSaved-search alertsNot describedNot describedNot described
Cortellis Competitive Intelligence54YesCurrent and historical statusWord and Excel exportsYesYes5
AdisInsight612YesPhase and trial-status changesSource XML and data feedsYesNot described
GlobalData Clinical Trials Database7YesDaily collection; 1 to 2 day lagAPI and cloud dataset deliveryNot describedNo7
DataLookout3YesField-change summariesCSV export on ProNot describedNot described

Not described means the provider's public pages do not document it.

Prices on record

Quote only means no price is published.

ProductPrice on record
Maven BioQuote only13
Citeline Pharmaprojects+Quote only2
Cortellis Competitive IntelligenceQuote only4
AdisInsightQuote only6
GlobalData Clinical Trials Database£1,000 listed dataset price7
DataLookoutFree $0; Pro $49/month or $490/year, USD3

Maven Bio

Best for

Keeping pipeline evidence connected to the assessments, spreadsheets, and presentations used in recurring decisions.

Maven Bio monitors clinical, regulatory, company, and market-access developments against a team's priorities and applies source-linked edits to selected project files. The maintained Word, Excel, and PowerPoint files include revision history and rollback1.

Biopharma data is built in, linking drug, trial, company, deal, and financing records to source documents. Maven Bio's Claude listing names monitoring for FDA actions, clinical trial readouts, and press releases, while MCP, API, and connectors bring the evidence into other research environments1014.

A recurring pipeline review can begin with an uploaded asset roster, an earlier deliverable, and the team's assessment criteria, rather than a newly assembled output format each time15. Maven Bio's workflow page describes refining proposed research steps, setting source preferences, and running the assignment on demand or on a schedule15. The assignment can use connected internal data and retain open research questions for the next review, so the repeatable task includes the team's context as well as the external evidence15.

Teams can add third-party reports and project documents they are permitted to use, with the available integration depending on the source license16.

For data delivery, the API exposes structured records and monitoring findings with source references, while webhooks notify a connected system when new findings become available14. That is a separate integration route from the assistant connection and the maintained files in a Maven Bio project141.

Teams can define a Maven Bio watch around an indication, target, mechanism, or modality, as well as named assets, so emerging competitors can enter the research scope16. Its research agent supports an initial approach for review, attached files, and changes to the instructions during the investigation, with automatic model routing or a choice among available models17. Source passages and built-in claim checking accompany the assessment1716.

Coverage

As of October 2026, Maven Bio covers 100,000+ drug products and 30,000+ companies across all therapeutic areas, drawing on 11 source classes worldwide16.

Price on record

Quote only13. Annual team licensing includes pooled AI credits, with the quote scoped around data rights, team access, AI usage, MCP access, API delivery, and integrations13.

Pros

Pipeline developments can update the working assessment with a source behind each edit1; linked records and integrations connect asset research with company and financing context1014.

Cons

The MCP connector is read-only11.

Citeline Pharmaprojects+

Best for

Mapping development competition across stages and comparing historical pipelines.

Pharmaprojects+ follows drug development from preclinical research to launch, including failed and withdrawn programs. Teams can filter assets by target, modality, geography, phase, and company, or investigate chemical, biological, and mechanistic comparators2.

Annual snapshots show earlier pipelines, while continuous curation and saved-search alerts support the current landscape. Ella answers pipeline questions with links to source records, and connections to Trialtrove+ and Sitetrove extend research into trials and sites2.

The analytical views examine how pipeline composition changes by mechanism, modality, geography, and market potential, including phase progression, discontinuation patterns, and launch timelines2. Company comparisons can separate disease, development stage, and trial activity, so a landscape can retain more detail than a single count of active assets2.

Citeline also provides access to its subject specialists through Ask the Analyst, while Ella builds and validates searches against the same curated pipeline collection2. The source-record links attached to Ella's answers provide a route back to the asset entries used to construct a landscape2.

The public product history identifies Pharmaprojects+ as the current version of Pharmaprojects, retaining the existing curated collection while adding Company Compare, Drug Similarity, and Ella2. Citeline describes the curation team as aligned to therapeutic areas and responsible for monitoring and verifying developments before updating profiles, with subject-specialist questions included alongside the analytical functions2.

Coverage

Citeline publishes 100,000+ drug profiles and 58,000+ sources for continuous curation, with annual historical snapshots dating to 19952. The published search dimensions include more than 3,700 mechanisms and 1,100 targets, alongside dedicated coverage of more than 750 rare diseases with orphan designations, program status, and sponsors2.

Price on record

Quote only2. Citeline asks buyers to discuss the use case, access needs, and package for their organization2.

Pros

Failed and withdrawn assets remain available alongside active development programs2; company comparisons and drug similarity searches offer distinct ways to define the competitive set2.

Cons

Historical snapshots use annual intervals, leaving changes between those dates outside that comparison2.

Cortellis Competitive Intelligence

Best for

Researching development status alongside company pipelines, deals, and commercial forecasts.

Cortellis CCI's MCP service retrieves drug profiles, status by indication and country, company pipelines, deals, and consensus forecasts. Responses link to the underlying Cortellis drug records5.

The Drugs API includes current and historical development information, with active and inactive programs informed by clinical results, company releases, literature, and conference findings. It supports research from discovery and preclinical development through launch, with Word and Excel among its export formats4.

The drug collection includes chemical structures, mechanisms of action, indications, and the companies involved in discovery and development, with more than 20 filters for narrowing the competitive set4. Reported sales and forecasts are available for companies marketing a drug, while the late-stage and launched-drug content includes assessments of strengths, weaknesses, opportunities, and threats4. The published update process is daily and combines manual curation with editorial review and fact validation4.

Within MCP, a compact drug overview can be followed by a specific section or an answer tailored to the research question, and drug searches can return CSV results5. Analytical plans are validated before execution, with visualizations available in hosts that support the documented rich interface5.

Coverage

Clarivate's Drugs API page reports more than 80,000 drugs and biologics in active or inactive development across more than 2,300 diseases4.

Price on record

Quote only4. Clarivate describes a paid license for the Drugs API and directs buyers to its team for access terms4.

Pros

Indication and country detail preserve differences within a program's development status5; MCP and API delivery support assistant-based research and programmatic retrieval54.

Cons

CCI MCP is not supported in Microsoft 365 Copilot Chat5.

AdisInsight

Best for

Following development milestones with connected trial and safety evidence.

AdisInsight combines curated drug-development information with trials, deals, patents, and safety. Its MCP operations distinguish phase progression, filing, approval, launch, suspension, discontinuation, and withdrawal612.

Drug timelines show development by disease and the milestones associated with each phase, while trial timelines preserve study-status changes. The service also retrieves detailed editorial narratives, related tables, and safety reports, with API and XML delivery described on the main site126.

Drug searches can combine disease, development phase, company, mechanism, target, route, formulation, country, designation, and date, while trial searches add study status, patient information, and results12. A development timeline can show the highest phase by disease over time, with optional detail for individual country, route, formulation, and patient-segment development lines12. Related tables are retrievable a page at a time with totals, including organizations, brand names, and development history, so a pipeline assessment can inspect the records behind a summarized profile12.

The knowledge-base operation explains the datasets, fields, search matching, and relationships between records, including questions the data can and cannot answer12. AdisInsight's main service also describes indication dashboards and visualizations drawn from drug and trial search results6.

For trial histories, the MCP response distinguishes the current status from the date the record was first listed and the sequence of earlier statuses, returned in chronological order12. For drug histories, milestones such as first late-stage development, filing, approval, and launch retain country information, while a development line can close when it stops12.

Coverage

The MCP documentation identifies approximately 347,000 safety reports, including literature case reports of adverse drug reactions and other safety reports12.

Price on record

Quote only6. The product page directs buyers to its specialists and does not publish a subscription amount6.

Pros

Development histories retain discontinued and withdrawn programs12; separate drug and trial timelines keep program milestones distinct from study-status changes12.

Cons

MCP chart grouping is limited to one or two fields12.

GlobalData Clinical Trials Database

Best for

Using a multi-source clinical-trial dataset in pipeline research.

GlobalData compiles its Clinical Trials Database from government, nongovernment, and company registries, research publications, and scientific conferences. Its product page specifies daily collection, a 1 to 2 day lag, point-in-time data, and API or cloud delivery7.

The dataset concerns clinical studies. GlobalData's wider pharmaceutical offering separately describes drug databases, regulatory milestones, company news, deals, and forecasts18.

The dataset specification distinguishes its collection schedule from its delivery lag, and labels the collection as point-in-time data with no proprietary data or forecasts7. It uses GlobalData's industry taxonomy and identifies company locations by headquarters, providing a defined organizational field for a trial-data export7. Public and private companies are both within the stated company coverage, while the historical date and record count describe this particular dataset rather than the whole pharmaceutical offering7.

GlobalData's pharmaceutical platform separately includes regulatory milestone research and a catalyst calendar alongside its company and market content18. A comparison of the listed dataset and the broader platform therefore needs to retain which named offering supplies each field, because the dataset's public specification explicitly leaves forecasts out718.

Coverage

The Clinical Trials Database page lists 487,367 records and company coverage of 56,535 public and private organizations worldwide, with a historical start date of 19957.

Price on record

The Clinical Trials Database page lists £1,000 for the named dataset, without specifying a monthly or annual billing period7.

Pros

Trial research combines registry evidence with publication and conference sources7; API and cloud delivery provide data for analysis in other systems7.

Cons

This dataset contains no forecast data7.

DataLookout

Best for

Inspecting exact changes to watched ClinicalTrials.gov records.

DataLookout compares registry records each morning and displays old and new values for fields such as status, enrollment, dates, endpoints, interventions, sites, and results. Changes are grouped by severity3.

Teams can follow sponsors or diseases through watchlists, save searches, and receive daily or weekly email summaries. The dashboard includes read and handled states, while disease-area reports show sponsor activity, phase distribution, and recent protocol changes3.

The completion calendar organizes primary-completion and study-completion dates, with previews on Free and fuller calendar access on Pro3. A separate at-risk view flags completion dates that move back by at least 30 days, while landscape reports collect activity by sponsor, development phase, and recent protocol amendments3. The change feed distinguishes stopped trials, notable changes, and minor edits, allowing the researcher to inspect the underlying field difference before changing a pipeline assessment3.

Free supports 1 sponsor watchlist, 1 disease watchlist, 1 saved search, and 5 individually watched trials; Pro raises those limits to 10, 10, 10, and 25, respectively3. Daily checks and email summaries are available on both plans, while CSV export is listed for Pro3.

Coverage

DataLookout advertises search across 150,000+ trials, all drawn from the official ClinicalTrials.gov API3.

Price on record

Free is $0, while Pro is $49 per month or $490 per year in US dollars3.

Pros

Field-level comparisons make the substance of an amendment visible3; recurring summaries collect new trials and changes across watched sponsors or diseases3.

Cons

The single-registry source excludes developments reported only outside ClinicalTrials.gov3.

How to choose pharma pipeline tracking software

Start with the decision the pipeline research has to support, and define the indication, mechanism, development stage, and geography before selecting the records to compare24. A licensing assessment can require inactive programs and historical development context as well as the current competitor set, which is why the scope of Citeline's failed and withdrawn assets and Cortellis's active and inactive programs belongs in the evaluation24. For an ongoing portfolio review, distinguish a change in a particular study from a change in the drug's development line, using the separate trial-status and drug-phase histories documented by AdisInsight12.

Next, check where the work ends up between reviews, including the time between new evidence and the revised tracker, briefing, or portfolio presentation used in the decision1. Maven Bio documents selected-file maintenance with sources, history, and rollback, while Cortellis describes exports and DataLookout describes summaries and CSV delivery, giving the evaluation concrete outputs to inspect143. A useful evaluation can therefore follow the same evidence from retrieval through the intended deliverable, with a separate check of the API or MCP operations required to bring records into an assistant or an internal system14512.

Then test coverage against programs your team already follows, including known development milestones, registry amendments, result announcements, and discontinued programs when historical research is part of the decision1023. Preserve the indication, country, study, and date attached to each record, and compare the requested research period with the provider's stated annual snapshots, dated development timelines, or point-in-time dataset specifications2127. Finally, compare the quoted product scope with the intended use, since Maven Bio scopes data rights and integration access, GlobalData lists a specific dataset purchase, and DataLookout publishes separate watchlist and export allowances for its plans1373.

Frequently asked questions

What is pharma pipeline tracking software?

It organizes development programs and evidence about their progress, with the covered stages and record types varying by product23. Maven Bio connects drug, trial, and company evidence with ongoing monitoring, Pharmaprojects+ follows preclinical-to-launch development, and DataLookout follows registered clinical studies1023.

Is trial monitoring enough to track a whole pipeline?

Trial monitoring follows studies within the named source scope, while a development landscape can also include preclinical assets, inactive programs, and company relationships32. Pharmaprojects+ explicitly includes preclinical, failed, and withdrawn assets beyond the set of currently registered trials2.

How can teams continuously monitor competitors in pharma?

Maven Bio connects ongoing monitoring with source-linked revisions to selected project files, including history and rollback1. The maintained output can be downloaded in Word, Excel, and PowerPoint, and recurring assignments can use a prior deliverable, the team's source preferences, and a defined schedule115. API findings and webhook notifications provide an additional route for follow-up in connected systems14.

Can pipeline data be researched in Claude?

Maven Bio and Cortellis CCI document MCP connections for linked biopharma and commercial research inside an assistant105. AdisInsight also exposes drug and trial operations, including phase changes, trial-status changes, and detailed record retrieval12.

How are historical snapshots different from change alerts?

A snapshot represents a pipeline at a defined point in time, while an alert identifies a new development or changed record2. Pharmaprojects+ lists annual historical snapshots separately from saved-search alerts, so the snapshot interval does not define the frequency of its current-record updates2.

Does pipeline monitoring include clinical trial readouts?

Maven Bio's Claude listing explicitly includes monitoring for clinical trial readouts, FDA actions, and press releases10. Its platform connects those findings to drug, trial, and company context, with maintained-file updates available in selected projects101.

Can a trial database provide commercial forecasts?

That depends on the named product, since GlobalData labels its Clinical Trials Database as containing no forecast data7. Its wider pharmaceutical offering separately includes forecasts, which should remain distinct from the specification and listed price of the trial dataset187.

Why retain discontinued programs in a pipeline landscape?

Inactive programs preserve development history alongside the current competitive set2. Pharmaprojects+ retains failed and withdrawn assets and describes analysis of discontinuation patterns, phase progression, and launch timelines2.